MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
5.62
-0.14
-2.43%
Closed 16:47 07/01 EDT
OPEN
5.69
PREV CLOSE
5.76
HIGH
5.99
LOW
5.29
VOLUME
242.61K
TURNOVER
--
52 WEEK HIGH
17.94
52 WEEK LOW
3.350
MARKET CAP
122.61M
P/E (TTM)
-1.7506
1D
5D
1M
3M
1Y
5Y
1D
Aardvark Therapeutics announces annual shareholder meeting
PUBT · 2d ago
Weekly Report: what happened at AARD last week (0622-0626)?
Weekly Report · 2d ago
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
PR Newswire · 6d ago
Weekly Report: what happened at AARD last week (0615-0619)?
Weekly Report · 06/22 10:38
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
PR Newswire · 06/19 13:00
Weekly Report: what happened at AARD last week (0608-0612)?
Weekly Report · 06/15 10:38
Aardvark Therapeutics Implements Executive Retention Bonus Agreements
TipRanks · 06/12 21:24
Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59
Simply Wall St · 06/09 10:31
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.